Table 2.
Ongoing trials of PARP inhibitors in glioma.
| Clinical Trial | Phase | Study Population | Intervention | Status |
|---|---|---|---|---|
| PARP Inhibition with Radiotherapy or Tumor Treating Fields | ||||
|
NCT03212742 [55] (OLA-TMZ-RTE-01) |
1/2a | Newly diagnosed glioblastoma | Radiotherapy with olaparib/temozolomide, then olaparib/temozolomide |
Recruiting |
| CRUKD/16/010 [56] (PARADIGM-2) |
1 | Newly diagnosed glioblastoma |
MGMT-methylated cohort: Radiotherapy with olaparib/temozolomide, then olaparib/temozolomide MGMT-unmethylated cohort: Radiotherapy with olaparib, then olaparib |
Recruiting |
| NCT05076513 | 0 “trigger” | Newly diagnosed glioblastoma (Cohort A) | Radiotherapy with niraparib, then niraparib |
Recruiting |
| NCT04221503 | 2 | Recurrent glioblastoma | Tumor treating fields with niraparib | Recruiting |
| NCT03581292 | 2 | Newly diagnosed high-grade glioma; H3 K27M-wildtype; BRAFV600E-wildtype; children/young adults |
Radiotherapy with veliparib, then veliparib/temozolomide |
Completed accrual |
| PARP Inhibition with Chemotherapy or Antiangiogenics | ||||
| NCT02974621 | 2 | Recurrent glioblastoma | Olaparib/cediranib vs. bevacizumab | Completed accrual |
|
NCT02152982 (Alliance A071102) |
2/3 | Newly diagnosed glioblastoma; MGMT-methylated |
Veliparib/temozolomide | Completed accrual |
| NCT04552977 | 2 | Recurrent glioblastoma | Fluzoparil/temozolomide | Not yet open |
| NCT04910022 | 1/2 | Recurrent glioblastoma | NMS-03305293/temozolomide | Not yet open |
| PARP Inhibition in IDH-Mutant Glioma | ||||
|
NCT03212274 (ETCTN-10129) |
2 | Recurrent IDH-mutant glioma, cholangiocarcinoma or other solid tumor | Olaparib | Recruiting |
| NCT05076513 | 0 “trigger” | Recurrent IDH-mutant glioma (Cohort B) | Niraparib | Recruiting |
|
NCT04740190 (TAC-GReD) |
2 | Recurrent high-grade glioma; DNA damage repair deficiency e.g., IDH-mutant, PTEN-mutant, BRCAness signature |
Radiotherapy with talazoparib/carboplatin | Recruiting |
|
NCT03914742 (ABTC-1801) |
1/2 | Recurrent IDH-mutant glioma | Pamiparib/temozolomide | Recruiting |
|
NCT03749187 (PNOC-017) |
1 | Recurrent IDH-mutant glioma; children/young adults |
Pamiparib/temozolomide | Recruiting |